Sarcoma Treatment in the Era of Molecular Medicine

Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.

Citing Articles

Osteosarcoma and Ewing Sarcoma of Bone: An Italian Mono-Institutional Epidemiological Study.

Ferrari C, Magagnoli G, Laranga R, Bianchi G, Carretta E, Cesari M Diagnostics (Basel). 2025; 15(3).

PMID: 39941258 PMC: 11817308. DOI: 10.3390/diagnostics15030328.

Exploring CX3CR1 as a prognostic biomarker and immunotherapeutic target in sarcoma.

Li T, Li X, Kang P, Zhao J Transl Oncol. 2025; 53:102283.

PMID: 39837057 PMC: 11787715. DOI: 10.1016/j.tranon.2025.102283.

CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma - a short report.

Young R, Chowdry J, Cochonneau D, Heymann D Cancer Drug Resist. 2025; 7():51.

PMID: 39802953 PMC: 11724351. DOI: 10.20517/cdr.2024.149.

Bayesian unsupervised clustering identifies clinically relevant osteosarcoma subtypes.

Llaneza-Lago S, Fraser W, Green D Brief Bioinform. 2024; 26(1).

PMID: 39701601 PMC: 11658815. DOI: 10.1093/bib/bbae665.

Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy.

Taurin S, Alzahrani R, AlOraibi S, Ashi L, Alharmi R, Hassani N Transl Oncol. 2024; 51:102226.

PMID: 39622151 PMC: 11647637. DOI: 10.1016/j.tranon.2024.102226.

References

Kolosenko I, Avnet S, Baldini N, Viklund J, De Milito A . Therapeutic implications of tumor interstitial acidification. Semin Cancer Biol. 2017; 43:119-133. DOI: 10.1016/j.semcancer.2017.01.008. View

Brien G, Remillard D, Shi J, Hemming M, Chabon J, Wynne K . Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 2018; 7. PMC: 6277197. DOI: 10.7554/eLife.41305. View

Ali N, Niada S, Brini A, Morris M, Kurusamy S, Alholle A . Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone. J Pathol. 2018; 247(2):166-176. PMC: 8033574. DOI: 10.1002/path.5176. View

Kumar H, Heer K, Lee P, Duthie G, Macdonald A, Greenman J . Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res. 1998; 4(5):1279-85. View

Perut F, Roncuzzi L, Zini N, Massa A, Baldini N . Extracellular Nanovesicles Secreted by Human Osteosarcoma Cells Promote Angiogenesis. Cancers (Basel). 2019; 11(6). PMC: 6627280. DOI: 10.3390/cancers11060779. View

Trama A, Badalamenti G, Baldi G, Brunello A, Caira M, Drove N . Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes. Cancer Epidemiol. 2019; 59:258-264. DOI: 10.1016/j.canep.2019.02.012. View

Sundara Y, Kostine M, Cleven A, Bovee J, Schilham M, Cleton-Jansen A . Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2016; 66(1):119-128. PMC: 5222929. DOI: 10.1007/s00262-016-1925-3. View

Cain D, Wacnik P, Turner M, Wendelschafer-Crabb G, Kennedy W, Wilcox G . Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J Neurosci. 2001; 21(23):9367-76. PMC: 6763931. View

Boonstra P, Ter Elst A, Tibbesma M, Bosman L, Mathijssen R, Atrafi F . A single digital droplet PCR assay to detect multiple exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. Oncotarget. 2018; 9(17):13870-13883. PMC: 5862622. DOI: 10.18632/oncotarget.24493. View

10.

Ioannidis J, Lau J . 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med. 2003; 44(5):717-24. View

11.

Mihaly D, Nagy N, Papp G, Papai Z, Sapi Z . Release of circulating tumor cells and cell-free nucleic acids is an infrequent event in synovial sarcoma: liquid biopsy analysis of 15 patients diagnosed with synovial sarcoma. Diagn Pathol. 2018; 13(1):81. PMC: 6191904. DOI: 10.1186/s13000-018-0756-2. View

12.

Dumars C, Ngyuen J, Gaultier A, Lanel R, Corradini N, Gouin F . Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma. Oncotarget. 2016; 7(48):78343-78354. PMC: 5346643. DOI: 10.18632/oncotarget.13055. View

13.

Rougraff B, Simon M, Kneisl J, Greenberg D, Mankin H . Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am. 1994; 76(5):649-56. DOI: 10.2106/00004623-199405000-00004. View

14.

Liu Y, Mi Y, Mueller T, Kreibich S, Williams E, van Drogen A . Multi-omic measurements of heterogeneity in HeLa cells across laboratories. Nat Biotechnol. 2019; 37(3):314-322. DOI: 10.1038/s41587-019-0037-y. View

15.

Bonuccelli G, Avnet S, Grisendi G, Salerno M, Granchi D, Dominici M . Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells. Oncotarget. 2014; 5(17):7575-88. PMC: 4202145. DOI: 10.18632/oncotarget.2243. View

16.

Scholten 2nd D, Timmer C, Peacock J, Pelle D, Williams B, Steensma M . Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells. PLoS One. 2014; 9(10):e111431. PMC: 4210185. DOI: 10.1371/journal.pone.0111431. View

17.

Cardoso E, Guidi M, Blanchet B, Schneider M, Decosterd L, Buclin T . Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. Ther Drug Monit. 2019; 42(1):33-44. DOI: 10.1097/FTD.0000000000000699. View

18.

Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K . Synovial sarcoma is a stem cell malignancy. Stem Cells. 2010; 28(7):1119-31. DOI: 10.1002/stem.452. View

19.

Genadry K, Pietrobono S, Rota R, Linardic C . Soft Tissue Sarcoma Cancer Stem Cells: An Overview. Front Oncol. 2018; 8:475. PMC: 6212576. DOI: 10.3389/fonc.2018.00475. View

20.

Shimizu T, Sugihara E, Yamaguchi-Iwai S, Tamaki S, Koyama Y, Kamel W . IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress. Cancer Res. 2014; 74(22):6531-41. DOI: 10.1158/0008-5472.CAN-14-0914. View